These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 33183102)

  • 1. Drug repurposing: new strategies for addressing COVID-19 outbreak.
    Shende P; Khanolkar B; Gaud RS
    Expert Rev Anti Infect Ther; 2021 Jun; 19(6):689-706. PubMed ID: 33183102
    [No Abstract]   [Full Text] [Related]  

  • 2. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action.
    Yousefi H; Mashouri L; Okpechi SC; Alahari N; Alahari SK
    Biochem Pharmacol; 2021 Jan; 183():114296. PubMed ID: 33191206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
    Mishra J; Prasun C; Sahoo PK; Nair MS
    Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability.
    Debnath SK; Debnath M; Srivastava R; Omri A
    Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1187-1204. PubMed ID: 35615888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19: Potential Repurposing Drugs.
    Leowattana W
    Infect Disord Drug Targets; 2022; 22(1):e110122191924. PubMed ID: 33645490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches.
    Watashi K
    Biochem Biophys Res Commun; 2021 Jan; 538():137-144. PubMed ID: 33272566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
    Akilesh SM; J R; Palanisamy D; Wadhwani A
    Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
    Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D
    Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Old and re-purposed drugs for the treatment of COVID-19.
    Jean SS; Hsueh PR
    Expert Rev Anti Infect Ther; 2020 Sep; 18(9):843-847. PubMed ID: 32419524
    [No Abstract]   [Full Text] [Related]  

  • 11. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
    Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
    J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients.
    Ghanbari R; Teimoori A; Sadeghi A; Mohamadkhani A; Rezasoltani S; Asadi E; Jouyban A; Sumner SC
    Future Microbiol; 2020 Dec; 15():1747-1758. PubMed ID: 33404263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targets and potential agents for the treatment of COVID-19.
    Wu Y; Li Z; Zhao YS; Huang YY; Jiang MY; Luo HB
    Med Res Rev; 2021 May; 41(3):1775-1797. PubMed ID: 33393116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of repurposed drugs on the symptomatic COVID-19 patients.
    Hussain I; Hussain A; Alajmi MF; Rehman MT; Amir S
    J Infect Public Health; 2021 Jan; 14(1):24-38. PubMed ID: 33341481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.
    Mohamed K; Yazdanpanah N; Saghazadeh A; Rezaei N
    Bioorg Chem; 2021 Jan; 106():104490. PubMed ID: 33261845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug repurposing strategies and key challenges for COVID-19 management.
    Mule S; Singh A; Greish K; Sahebkar A; Kesharwani P; Shukla R
    J Drug Target; 2022 Apr; 30(4):413-429. PubMed ID: 34854327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment.
    Taibe NS; Kord MA; Badawy MA; Shytaj IL; Elhefnawi MM
    Ther Adv Respir Dis; 2022; 16():17534666221132736. PubMed ID: 36282077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase.
    Khan S; Attar F; Bloukh SH; Sharifi M; Nabi F; Bai Q; Khan RH; Falahati M
    Int J Biol Macromol; 2021 Jun; 181():605-611. PubMed ID: 33766591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Existing Drugs Considered as Promising in COVID-19 Therapy.
    Janik E; Niemcewicz M; Podogrocki M; Saluk-Bijak J; Bijak M
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34063964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target identification for repurposed drugs active against SARS-CoV-2 via high-throughput inverse docking.
    Ribone SR; Paz SA; Abrams CF; Villarreal MA
    J Comput Aided Mol Des; 2022 Jan; 36(1):25-37. PubMed ID: 34825285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.